SG11202001301RA - The salts of a compound and the crystalline forms thereof - Google Patents

The salts of a compound and the crystalline forms thereof

Info

Publication number
SG11202001301RA
SG11202001301RA SG11202001301RA SG11202001301RA SG11202001301RA SG 11202001301R A SG11202001301R A SG 11202001301RA SG 11202001301R A SG11202001301R A SG 11202001301RA SG 11202001301R A SG11202001301R A SG 11202001301RA SG 11202001301R A SG11202001301R A SG 11202001301RA
Authority
SG
Singapore
Prior art keywords
salts
compound
crystalline forms
crystalline
forms
Prior art date
Application number
SG11202001301RA
Inventor
Zhenping Wu
Wenji Li
Ling Feng
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of SG11202001301RA publication Critical patent/SG11202001301RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08Acetic acid
    • C07C53/10Salts thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11202001301RA 2017-08-22 2018-08-22 The salts of a compound and the crystalline forms thereof SG11202001301RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710723169.3A CN109422741A (en) 2017-08-22 2017-08-22 The salt and its crystal form of compound
PCT/CN2018/101699 WO2019037737A1 (en) 2017-08-22 2018-08-22 The salts of a compound and the crystalline forms thereof

Publications (1)

Publication Number Publication Date
SG11202001301RA true SG11202001301RA (en) 2020-03-30

Family

ID=65439343

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001301RA SG11202001301RA (en) 2017-08-22 2018-08-22 The salts of a compound and the crystalline forms thereof

Country Status (18)

Country Link
US (2) US11396507B2 (en)
EP (1) EP3672972A4 (en)
JP (1) JP7162964B2 (en)
KR (1) KR102650181B1 (en)
CN (4) CN109422741A (en)
AU (1) AU2018320010B2 (en)
BR (1) BR112020003617A2 (en)
CA (1) CA3072525A1 (en)
CL (1) CL2020000439A1 (en)
EA (1) EA202090532A1 (en)
IL (1) IL272835A (en)
MX (1) MX2020002015A (en)
PH (1) PH12020500366A1 (en)
SG (1) SG11202001301RA (en)
TW (1) TWI816690B (en)
UA (1) UA125942C2 (en)
WO (1) WO2019037737A1 (en)
ZA (1) ZA202001029B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114835682B (en) * 2022-06-17 2024-04-26 华东理工常熟研究院有限公司 Imidacloprid salt and preparation method and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012167423A1 (en) * 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
CN105732596B (en) * 2012-11-19 2019-05-28 齐鲁制药有限公司 N- [the chloro- 4- of 3- (3- fluorine benzyloxy) phenyl] -6- [5- [[2- (methanesulfinyl) ethyl] amino] methyl] -2- furyl] -4- quinazoline amine polymorph and preparation method thereof

Also Published As

Publication number Publication date
ZA202001029B (en) 2022-07-27
UA125942C2 (en) 2022-07-13
EP3672972A4 (en) 2021-03-24
JP2020532510A (en) 2020-11-12
AU2018320010A1 (en) 2020-02-27
US20210047318A1 (en) 2021-02-18
CA3072525A1 (en) 2019-02-28
IL272835A (en) 2020-04-30
WO2019037737A1 (en) 2019-02-28
CN111094284A (en) 2020-05-01
BR112020003617A2 (en) 2020-09-01
EP3672972A1 (en) 2020-07-01
US20220389012A1 (en) 2022-12-08
TW201912642A (en) 2019-04-01
PH12020500366A1 (en) 2021-01-11
KR102650181B1 (en) 2024-03-21
KR20200044020A (en) 2020-04-28
JP7162964B2 (en) 2022-10-31
CN109422741A (en) 2019-03-05
US11396507B2 (en) 2022-07-26
EA202090532A1 (en) 2021-02-11
CN114369093A (en) 2022-04-19
MX2020002015A (en) 2020-07-20
CN114044776A (en) 2022-02-15
TWI816690B (en) 2023-10-01
CL2020000439A1 (en) 2020-08-07
AU2018320010B2 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
IL273730A (en) Crystalline forms
IL270872A (en) Crystalline forms of a fgfr inhibitor and processes for preparing the same
IL268852A (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
ZA201903093B (en) Crystalline forms of a magl inhibitor
IL285686B (en) Crystalline solid forms of a bet inhibitor
IL279195A (en) Novel salts and crystals
PL3532457T3 (en) Crystalline forms of hydroxynorketamine
HK1199453A1 (en) A crystal form of icaritin compound, a medicament comprising the crystalline form and use thereof
IL281168A (en) Crystalline forms of a quinazole compound and its hydrochloride salts
IL270961A (en) Crystalline form of n-butyldeoxygalactonojirimycin
IL272835A (en) The salts of a compound and the crystalline forms thereof
IL278054A (en) The crystalline forms of a compound
IL274758A (en) Crystalline polymorphs of pracinostat and pracinostat salts
FI3686191T3 (en) Crystalline sulfamide compound
EP3630750A4 (en) The salts of a compound and the crystalline forms thereof
IL292206A (en) The salts of a compound and the crystalline forms thereof
SG11202105355XA (en) Crystalline salts of corydalmine
IL276108A (en) Fasoracetam crystalline forms
IL270937A (en) Crystalline forms of seletalisib
GB201715010D0 (en) Crystalline forms
GB201704789D0 (en) Crystalline compounds